About
Lauren completed her PhD in medical biochemistry under the supervision of Prof. Jonathan Blackburn at the University of Cape Town (UCT) in 2014. During her PhD she spent a year as a visiting Commonwealth PhD Scholar in Sir Tom Blundell’s biocomputing group at the University of Cambridge in the UK, where she gained valuable experience in protein modelling. Following her PhD, she completed her postdoctoral research under the guidance of Prof. Kelly Chibale and Prof. Edward Sturrock at UCT. During her doctoral and postdoctoral studies, Lauren worked on a variety of enzyme systems including human cytochrome P450 enzymes, human zinc metallopeptidases and protein and lipid kinases, gaining expertise in recombinant protein expression, enzymology, assay development and structure-based drug design.
In 2019 Lauren joined the Holistic Drug Discovery and Development (H3D) Centre to establish an enzymology platform focused on Plasmodium kinases as targets for malaria drug discovery. In 2020 she was awarded a 2-year Future Leaders – African Independent Research (FLAIR) Fellowship to expand her work on Plasmodium kinases. The FLAIR Fellowship Programme is a partnership between the African Academy of Sciences and the Royal Society funded by the UK Government’s Global Challenges Research Fund.
Lauren is now a Chief Investigator at H3D where she leads the Enzymology Platform supporting malaria, TB and AMR target-based drug discovery projects. Lauren also serves as an H3D representative for the Malaria Drug Accelerator (MalDA) Consortium, an international drug discovery platform made up of academic and industry partners funded by the Gates Foundation.
Selected publications
1485676
{1485676:S8FA6DF2},{1485676:JMZX2PFB},{1485676:5STEEKV3},{1485676:ZAK6P2MK},{1485676:YEJVGNJU},{1485676:IXTDQH9R}
1
modern-language-association
50
date
1
1
500
https://biophysicsworkshop.co.za/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22S8FA6DF2%22%2C%22library%22%3A%7B%22id%22%3A1485676%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dziwornu%20et%20al.%22%2C%22parsedDate%22%3A%222024-07-11%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDziwornu%2C%20Godwin%20Akpeko%2C%20et%20al.%20%26%23x201C%3B2%2C8-Disubstituted-1%2C5-Naphthyridines%20as%20Dual%20Inhibitors%20of%20Plasmodium%20Falciparum%20Phosphatidylinositol-4-Kinase%20and%20Hemozoin%20Formation%20with%20In%20Vivo%20Efficacy.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Medicinal%20Chemistry%3C%5C%2Fi%3E%2C%20vol.%2067%2C%20no.%2013%2C%20July%202024%2C%20pp.%2011401%26%23×2013%3B20%2C%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facs.jmedchem.4c01154%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facs.jmedchem.4c01154%3C%5C%2Fa%3E.%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fbiophysicsworkshop.co.za%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D1485676%26amp%3Bitem_key%3DS8FA6DF2%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%222%2C8-Disubstituted-1%2C5-naphthyridines%20as%20Dual%20Inhibitors%20of%20Plasmodium%20falciparum%20Phosphatidylinositol-4-kinase%20and%20Hemozoin%20Formation%20with%20In%20Vivo%20Efficacy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Godwin%20Akpeko%22%2C%22lastName%22%3A%22Dziwornu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Donald%22%2C%22lastName%22%3A%22Seanego%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%22%2C%22lastName%22%3A%22Fienberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monica%22%2C%22lastName%22%3A%22Clements%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jasmin%22%2C%22lastName%22%3A%22Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Venkata%20S.%22%2C%22lastName%22%3A%22Sypu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sauvik%22%2C%22lastName%22%3A%22Samanta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashlyn%20D.%22%2C%22lastName%22%3A%22Bhana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%20M.%22%2C%22lastName%22%3A%22Korkor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Larnelle%20F.%22%2C%22lastName%22%3A%22Garnie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Teixeira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%20J.%22%2C%22lastName%22%3A%22Wicht%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dale%22%2C%22lastName%22%3A%22Taylor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%22%2C%22lastName%22%3A%22Olckers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathew%22%2C%22lastName%22%3A%22Njoroge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liezl%22%2C%22lastName%22%3A%22Gibhard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolaas%22%2C%22lastName%22%3A%22Salomane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergio%22%2C%22lastName%22%3A%22Wittlin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rohit%22%2C%22lastName%22%3A%22Mahato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnish%22%2C%22lastName%22%3A%22Chakraborty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Sevilleno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachael%22%2C%22lastName%22%3A%22Coyle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcus%20C.%20S.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luiz%20C.%22%2C%22lastName%22%3A%22Godoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charisse%20Flerida%22%2C%22lastName%22%3A%22Pasaje%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacquin%20C.%22%2C%22lastName%22%3A%22Niles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janette%22%2C%22lastName%22%3A%22Reader%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariette%22%2C%22lastName%22%3A%22van%20der%20Watt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lyn-Mari%5Cu00e9%22%2C%22lastName%22%3A%22Birkholtz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judith%20M.%22%2C%22lastName%22%3A%22Bolscher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marloes%20H.%20C.%22%2C%22lastName%22%3A%22de%20Bruijni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20B.%22%2C%22lastName%22%3A%22Coulson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20S.%22%2C%22lastName%22%3A%22Basarab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandeep%20R.%22%2C%22lastName%22%3A%22Ghorpade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%22%2C%22lastName%22%3A%22Chibale%22%7D%5D%2C%22abstractNote%22%3A%22Structure%5Cu2013activity%20relationship%20studies%20of%202%2C8-disubstituted-1%2C5-naphthyridines%2C%20previously%20reported%20as%20potent%20inhibitors%20of%20Plasmodium%20falciparum%20%28Pf%29%20phosphatidylinositol-4-kinase%20%5Cu03b2%20%28PI4K%29%2C%20identified%201%2C5-naphthyridines%20with%20basic%20groups%20at%208-position%2C%20which%20retained%20Plasmodium%20PI4K%20inhibitory%20activity%20but%20switched%20primary%20mode%20of%20action%20to%20the%20host%20hemoglobin%20degradation%20pathway%20through%20inhibition%20of%20hemozoin%20formation.%20These%20compounds%20showed%20minimal%20off-target%20inhibitory%20activity%20against%20the%20human%20phosphoinositide%20kinases%20and%20MINK1%20and%20MAP4K%20kinases%2C%20which%20were%20associated%20with%20the%20teratogenicity%20and%20testicular%20toxicity%20observed%20in%20rats%20for%20the%20PfPI4K%20inhibitor%20clinical%20candidate%20MMV390048.%20A%20representative%20compound%20from%20the%20series%20retained%20activity%20against%20field%20isolates%20and%20lab-raised%20drug-resistant%20strains%20of%20Pf.%20It%20was%20efficacious%20in%20the%20humanized%20NSG%20mouse%20malaria%20infection%20model%20at%20a%20single%20oral%20dose%20of%2032%20mg%5C%2Fkg.%20This%20compound%20was%20nonteratogenic%20in%20the%20zebrafish%20embryo%20model%20of%20teratogenicity%20and%20has%20a%20low%20predicted%20human%20dose%2C%20indicating%20that%20this%20series%20has%20the%20potential%20to%20deliver%20a%20preclinical%20candidate%20for%20malaria.%22%2C%22date%22%3A%222024-07-11%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1021%5C%2Facs.jmedchem.4c01154%22%2C%22ISSN%22%3A%220022-2623%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facs.jmedchem.4c01154%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222024-11-09T19%3A48%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22IXTDQH9R%22%2C%22library%22%3A%7B%22id%22%3A1485676%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mogwera%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMogwera%2C%20Koketso%20S.%20P.%2C%20et%20al.%20%26%23x201C%3BDeveloping%20Kinase%20Inhibitors%20for%20Malaria%3A%20An%20Opportunity%20or%20Liability%3F%26%23x201D%3B%20%3Ci%3ETrends%20in%20Parasitology%3C%5C%2Fi%3E%2C%20vol.%2039%2C%20no.%209%2C%20Sept.%202023%2C%20pp.%20720%26%23×2013%3B31%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.pt.2023.06.001%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.pt.2023.06.001%3C%5C%2Fa%3E.%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fbiophysicsworkshop.co.za%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D1485676%26amp%3Bitem_key%3DIXTDQH9R%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Developing%20kinase%20inhibitors%20for%20malaria%3A%20an%20opportunity%20or%20liability%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Koketso%20S.%20P.%22%2C%22lastName%22%3A%22Mogwera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%22%2C%22lastName%22%3A%22Chibale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20B.%22%2C%22lastName%22%3A%22Arendse%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-09-01%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.pt.2023.06.001%22%2C%22ISSN%22%3A%221471-4922%2C%201471-5007%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.cell.com%5C%2Ftrends%5C%2Fparasitology%5C%2Fabstract%5C%2FS1471-4922%2823%2900132-0%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222024-11-09T19%3A49%3A56Z%22%7D%7D%2C%7B%22key%22%3A%22YEJVGNJU%22%2C%22library%22%3A%7B%22id%22%3A1485676%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Arendse%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-19%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EArendse%2C%20Lauren%20B.%2C%20et%20al.%20%26%23x201C%3BThe%20Anticancer%20Human%20MTOR%20Inhibitor%20Sapanisertib%20Potently%20Inhibits%20Multiple%20Plasmodium%20Kinases%20and%20Life%20Cycle%20Stages.%26%23x201D%3B%20%3Ci%3EScience%20Translational%20Medicine%3C%5C%2Fi%3E%2C%20vol.%2014%2C%20no.%20667%2C%20Oct.%202022%2C%20p.%20eabo7219%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscitranslmed.abo7219%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscitranslmed.abo7219%3C%5C%2Fa%3E.%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fbiophysicsworkshop.co.za%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D1485676%26amp%3Bitem_key%3DYEJVGNJU%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20anticancer%20human%20mTOR%20inhibitor%20sapanisertib%20potently%20inhibits%20multiple%20Plasmodium%20kinases%20and%20life%20cycle%20stages%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20B.%22%2C%22lastName%22%3A%22Arendse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20M.%22%2C%22lastName%22%3A%22Murithi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tarrick%22%2C%22lastName%22%3A%22Qahash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charisse%20Flerida%20A.%22%2C%22lastName%22%3A%22Pasaje%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luiz%20C.%22%2C%22lastName%22%3A%22Godoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sumanta%22%2C%22lastName%22%3A%22Dey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liezl%22%2C%22lastName%22%3A%22Gibhard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonja%22%2C%22lastName%22%3A%22Ghidelli-Disse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerard%22%2C%22lastName%22%3A%22Drewes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcus%22%2C%22lastName%22%3A%22Bantscheff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20J.%22%2C%22lastName%22%3A%22Lafuente-Monasterio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%22%2C%22lastName%22%3A%22Fienberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lynn%22%2C%22lastName%22%3A%22Wambua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Gachuhi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dina%22%2C%22lastName%22%3A%22Coertzen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mari%5Cu00ebtte%22%2C%22lastName%22%3A%22van%20der%20Watt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janette%22%2C%22lastName%22%3A%22Reader%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayesha%20S.%22%2C%22lastName%22%3A%22Aswat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erica%22%2C%22lastName%22%3A%22Erlank%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelius%22%2C%22lastName%22%3A%22Venter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nimisha%22%2C%22lastName%22%3A%22Mittal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Madeline%20R.%22%2C%22lastName%22%3A%22Luth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabine%22%2C%22lastName%22%3A%22Ottilie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20A.%22%2C%22lastName%22%3A%22Winzeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lizette%20L.%22%2C%22lastName%22%3A%22Koekemoer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lyn-Marie%22%2C%22lastName%22%3A%22Birkholtz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacquin%20C.%22%2C%22lastName%22%3A%22Niles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%22%2C%22lastName%22%3A%22Llin%5Cu00e1s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A.%22%2C%22lastName%22%3A%22Fidock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%22%2C%22lastName%22%3A%22Chibale%22%7D%5D%2C%22abstractNote%22%3A%22Compounds%20acting%20on%20multiple%20targets%20are%20critical%20to%20combating%20antimalarial%20drug%20resistance.%20Here%2C%20we%20report%20that%20the%20human%20%5Cu201cmammalian%20target%20of%20rapamycin%5Cu201d%20%28mTOR%29%20inhibitor%20sapanisertib%20has%20potent%20prophylactic%20liver%20stage%20activity%2C%20in%20vitro%20and%20in%20vivo%20asexual%20blood%20stage%20%28ABS%29%20activity%2C%20and%20transmission-blocking%20activity%20against%20the%20protozoan%20parasite%20Plasmodium%20spp.%20Chemoproteomics%20studies%20revealed%20multiple%20potential%20Plasmodium%20kinase%20targets%2C%20and%20potent%20inhibition%20of%20Plasmodium%20phosphatidylinositol%204-kinase%20type%20III%20beta%20%28PI4K%5Cu03b2%29%20and%20cyclic%20guanosine%20monophosphate%5Cu2013dependent%20protein%20kinase%20%28PKG%29%20was%20confirmed%20in%20vitro.%20Conditional%20knockdown%20of%20PI4K%5Cu03b2%20in%20ABS%20cultures%20modulated%20parasite%20sensitivity%20to%20sapanisertib%2C%20and%20laboratory-generated%20P.%20falciparum%20sapanisertib%20resistance%20was%20mediated%20by%20mutations%20in%20PI4K%5Cu03b2.%20Parasite%20metabolomic%20perturbation%20profiles%20associated%20with%20sapanisertib%20and%20other%20known%20PI4K%5Cu03b2%20and%5C%2For%20PKG%20inhibitors%20revealed%20similarities%20and%20differences%20between%20chemotypes%2C%20potentially%20caused%20by%20sapanisertib%20targeting%20multiple%20parasite%20kinases.%20The%20multistage%20activity%20of%20sapanisertib%20and%20its%20in%20vivo%20antimalarial%20efficacy%2C%20coupled%20with%20potent%20inhibition%20of%20at%20least%20two%20promising%20drug%20targets%2C%20provides%20an%20opportunity%20to%20reposition%20this%20pyrazolopyrimidine%20for%20malaria.%22%2C%22date%22%3A%222022-10-19%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1126%5C%2Fscitranslmed.abo7219%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.science.org%5C%2Fdoi%5C%2Fabs%5C%2F10.1126%5C%2Fscitranslmed.abo7219%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222024-11-09T19%3A49%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22JMZX2PFB%22%2C%22library%22%3A%7B%22id%22%3A1485676%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Arendse%20et%20al.%22%2C%22parsedDate%22%3A%222021-03-12%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EArendse%2C%20Lauren%20B.%2C%20et%20al.%20%26%23x201C%3BPlasmodium%20Kinases%20as%20Potential%20Drug%20Targets%20for%20Malaria%3A%20Challenges%20and%20Opportunities.%26%23x201D%3B%20%3Ci%3EACS%20Infectious%20Diseases%3C%5C%2Fi%3E%2C%20vol.%207%2C%20no.%203%2C%20Mar.%202021%2C%20pp.%20518%26%23×2013%3B34%2C%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facsinfecdis.0c00724%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facsinfecdis.0c00724%3C%5C%2Fa%3E.%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fbiophysicsworkshop.co.za%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D1485676%26amp%3Bitem_key%3DJMZX2PFB%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Plasmodium%20Kinases%20as%20Potential%20Drug%20Targets%20for%20Malaria%3A%20Challenges%20and%20Opportunities%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20B.%22%2C%22lastName%22%3A%22Arendse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%22%2C%22lastName%22%3A%22Wyllie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%22%2C%22lastName%22%3A%22Chibale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%20H.%22%2C%22lastName%22%3A%22Gilbert%22%7D%5D%2C%22abstractNote%22%3A%22Protein%20and%20phosphoinositide%20kinases%20have%20been%20successfully%20exploited%20as%20drug%20targets%20in%20various%20disease%20areas%2C%20principally%20in%20oncology.%20In%20malaria%2C%20several%20protein%20kinases%20are%20under%20investigation%20as%20potential%20drug%20targets%2C%20and%20an%20inhibitor%20of%20Plasmodium%20phosphatidylinositol%204-kinase%20type%20III%20beta%20%28PI4KIII%5Cu03b2%29%20is%20currently%20in%20phase%202%20clinical%20studies.%20In%20this%20Perspective%2C%20we%20review%20the%20potential%20of%20kinases%20as%20drug%20targets%20for%20the%20treatment%20of%20malaria.%20Kinases%20are%20known%20to%20be%20readily%20druggable%2C%20and%20many%20are%20essential%20for%20parasite%20survival.%20A%20key%20challenge%20in%20the%20design%20of%20Plasmodium%20kinase%20inhibitors%20is%20obtaining%20selectivity%20over%20the%20corresponding%20human%20orthologue%28s%29%20and%20other%20human%20kinases%20due%20to%20the%20highly%20conserved%20nature%20of%20the%20shared%20ATP%20binding%20site.%20Notwithstanding%20this%2C%20there%20are%20some%20notable%20differences%20between%20the%20Plasmodium%20and%20human%20kinome%20that%20may%20be%20exploitable.%20There%20is%20also%20the%20potential%20for%20designed%20polypharmacology%2C%20where%20several%20Plasmodium%20kinases%20are%20inhibited%20by%20the%20same%20drug.%20Prior%20to%20starting%20the%20drug%20discovery%20process%2C%20it%20is%20important%20to%20carefully%20assess%20potential%20kinase%20targets%20to%20ensure%20that%20the%20inhibition%20of%20the%20desired%20kinase%20will%20kill%20the%20parasites%20in%20the%20required%20life-cycle%20stages%20with%20a%20sufficiently%20fast%20rate%20of%20kill.%20Here%2C%20we%20highlight%20key%20target%20attributes%20and%20experimental%20approaches%20to%20consider%20and%20summarize%20the%20progress%20that%20has%20been%20made%20targeting%20Plasmodium%20PI4KIII%5Cu03b2%2C%20cGMP-dependent%20protein%20kinase%2C%20and%20cyclin-dependent-like%20kinase%203.%22%2C%22date%22%3A%222021-03-12%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1021%5C%2Facsinfecdis.0c00724%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facsinfecdis.0c00724%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222024-11-09T19%3A49%3A22Z%22%7D%7D%2C%7B%22key%22%3A%225STEEKV3%22%2C%22library%22%3A%7B%22id%22%3A1485676%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vanaerschot%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVanaerschot%2C%20Manu%2C%20et%20al.%20%26%23x201C%3BInhibition%20of%20Resistance-Refractory%20P.%20Falciparum%20Kinase%20PKG%20Delivers%20Prophylactic%2C%20Blood%20Stage%2C%20and%20Transmission-Blocking%20Antiplasmodial%20Activity.%26%23x201D%3B%20%3Ci%3ECell%20Chemical%20Biology%3C%5C%2Fi%3E%2C%20vol.%2027%2C%20no.%207%2C%20July%202020%2C%20pp.%20806-816.e8%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.chembiol.2020.04.001%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.chembiol.2020.04.001%3C%5C%2Fa%3E.%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fbiophysicsworkshop.co.za%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D1485676%26amp%3Bitem_key%3D5STEEKV3%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Inhibition%20of%20Resistance-Refractory%20P.%20falciparum%20Kinase%20PKG%20Delivers%20Prophylactic%2C%20Blood%20Stage%2C%20and%20Transmission-Blocking%20Antiplasmodial%20Activity%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manu%22%2C%22lastName%22%3A%22Vanaerschot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20M.%22%2C%22lastName%22%3A%22Murithi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charisse%20Flerida%20A.%22%2C%22lastName%22%3A%22Pasaje%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonja%22%2C%22lastName%22%3A%22Ghidelli-Disse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Dwomoh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%22%2C%22lastName%22%3A%22Bird%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natasha%22%2C%22lastName%22%3A%22Spottiswoode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nimisha%22%2C%22lastName%22%3A%22Mittal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20B.%22%2C%22lastName%22%3A%22Arendse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20S.%22%2C%22lastName%22%3A%22Owen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%20J.%22%2C%22lastName%22%3A%22Wicht%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giulia%22%2C%22lastName%22%3A%22Siciliano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Markus%22%2C%22lastName%22%3A%22B%5Cu00f6sche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomas%22%2C%22lastName%22%3A%22Yeo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20R.%20Santha%22%2C%22lastName%22%3A%22Kumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sachel%22%2C%22lastName%22%3A%22Mok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%20F.%22%2C%22lastName%22%3A%22Carpenter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marla%20J.%22%2C%22lastName%22%3A%22Giddins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olalla%22%2C%22lastName%22%3A%22Sanz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabine%22%2C%22lastName%22%3A%22Ottilie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pietro%22%2C%22lastName%22%3A%22Alano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%22%2C%22lastName%22%3A%22Chibale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%22%2C%22lastName%22%3A%22Llin%5Cu00e1s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Catrin%22%2C%22lastName%22%3A%22Uhlemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Delves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20B.%22%2C%22lastName%22%3A%22Tobin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Doerig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20A.%22%2C%22lastName%22%3A%22Winzeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcus%20C.%20S.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacquin%20C.%22%2C%22lastName%22%3A%22Niles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A.%22%2C%22lastName%22%3A%22Fidock%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-07-16%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.chembiol.2020.04.001%22%2C%22ISSN%22%3A%222451-9456%2C%202451-9448%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.cell.com%5C%2Fcell-chemical-biology%5C%2Fabstract%5C%2FS2451-9456%2820%2930115-X%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222024-11-09T19%3A49%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22ZAK6P2MK%22%2C%22library%22%3A%7B%22id%22%3A1485676%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Arendse%20et%20al.%22%2C%22parsedDate%22%3A%222019-10-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EArendse%2C%20Lauren%20B.%2C%20et%20al.%20%26%23x201C%3BNovel%20Therapeutic%20Approaches%20Targeting%20the%20Renin-Angiotensin%20System%20and%20Associated%20Peptides%20in%20Hypertension%20and%20Heart%20Failure.%26%23x201D%3B%20%3Ci%3EPharmacological%20Reviews%3C%5C%2Fi%3E%2C%20edited%20by%20Eric%20L.%20Barker%2C%20vol.%2071%2C%20no.%204%2C%20Oct.%202019%2C%20pp.%20539%26%23×2013%3B70%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1124%5C%2Fpr.118.017129%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1124%5C%2Fpr.118.017129%3C%5C%2Fa%3E.%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fbiophysicsworkshop.co.za%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D1485676%26amp%3Bitem_key%3DZAK6P2MK%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Novel%20Therapeutic%20Approaches%20Targeting%20the%20Renin-Angiotensin%20System%20and%20Associated%20Peptides%20in%20Hypertension%20and%20Heart%20Failure%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20B.%22%2C%22lastName%22%3A%22Arendse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20H.%20Jan%22%2C%22lastName%22%3A%22Danser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marko%22%2C%22lastName%22%3A%22Poglitsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rhian%20M.%22%2C%22lastName%22%3A%22Touyz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20C.%22%2C%22lastName%22%3A%22Burnett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Llorens-Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%20R.%22%2C%22lastName%22%3A%22Ehlers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20D.%22%2C%22lastName%22%3A%22Sturrock%22%7D%2C%7B%22creatorType%22%3A%22editor%22%2C%22firstName%22%3A%22Eric%20L.%22%2C%22lastName%22%3A%22Barker%22%7D%5D%2C%22abstractNote%22%3A%22Visual%20Overview%5CnDownload%20figureOpen%20in%20new%20tabDownload%20powerpoint%5Cn%5CnDespite%20the%20success%20of%20renin-angiotensin%20system%20%28RAS%29%20blockade%20by%20angiotensin-converting%20enzyme%20%28ACE%29%20inhibitors%20and%20angiotensin%20II%20type%201%20receptor%20%28AT1R%29%20blockers%2C%20current%20therapies%20for%20hypertension%20and%20related%20cardiovascular%20diseases%20are%20still%20inadequate.%20Identification%20of%20additional%20components%20of%20the%20RAS%20and%20associated%20vasoactive%20pathways%2C%20as%20well%20as%20new%20structural%20and%20functional%20insights%20into%20established%20targets%2C%20have%20led%20to%20novel%20therapeutic%20approaches%20with%20the%20potential%20to%20provide%20improved%20cardiovascular%20protection%20and%20better%20blood%20pressure%20control%20and%5C%2For%20reduced%20adverse%20side%20effects.%20The%20simultaneous%20modulation%20of%20several%20neurohumoral%20mediators%20in%20key%20interconnected%20blood%20pressure%5Cu2013regulating%20pathways%20has%20been%20an%20attractive%20approach%20to%20improve%20treatment%20efficacy%2C%20and%20several%20novel%20approaches%20involve%20combination%20therapy%20or%20dual-acting%20agents.%20In%20addition%2C%20increased%20understanding%20of%20the%20complexity%20of%20the%20RAS%20has%20led%20to%20novel%20approaches%20aimed%20at%20upregulating%20the%20ACE2%5C%2Fangiotensin-%281-7%29%5C%2FMas%20axis%20to%20counter-regulate%20the%20harmful%20effects%20of%20the%20ACE%5C%2Fangiotensin%20II%5C%2Fangiotensin%20III%5C%2FAT1R%20axis.%20These%20advances%20have%20opened%20new%20avenues%20for%20the%20development%20of%20novel%20drugs%20targeting%20the%20RAS%20to%20better%20treat%20hypertension%20and%20heart%20failure.%20Here%20we%20focus%20on%20new%20therapies%20in%20preclinical%20and%20early%20clinical%20stages%20of%20development%2C%20including%20novel%20small%20molecule%20inhibitors%20and%20receptor%20agonists%5C%2Fantagonists%2C%20less%20conventional%20strategies%20such%20as%20gene%20therapy%20to%20suppress%20angiotensinogen%20at%20the%20RNA%20level%2C%20recombinant%20ACE2%20protein%2C%20and%20novel%20bispecific%20designer%20peptides.%22%2C%22date%22%3A%222019%5C%2F10%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1124%5C%2Fpr.118.017129%22%2C%22ISSN%22%3A%220031-6997%2C%201521-0081%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fpharmrev.aspetjournals.org%5C%2Fcontent%5C%2F71%5C%2F4%5C%2F539%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222024-11-09T19%3A49%3A50Z%22%7D%7D%5D%7D
Dziwornu, Godwin Akpeko, et al. “2,8-Disubstituted-1,5-Naphthyridines as Dual Inhibitors of Plasmodium Falciparum Phosphatidylinositol-4-Kinase and Hemozoin Formation with In Vivo Efficacy.”
Journal of Medicinal Chemistry, vol. 67, no. 13, July 2024, pp. 11401–20,
https://doi.org/10.1021/acs.jmedchem.4c01154.
Cite
Mogwera, Koketso S. P., et al. “Developing Kinase Inhibitors for Malaria: An Opportunity or Liability?”
Trends in Parasitology, vol. 39, no. 9, Sept. 2023, pp. 720–31,
https://doi.org/10.1016/j.pt.2023.06.001.
Cite
Arendse, Lauren B., et al. “The Anticancer Human MTOR Inhibitor Sapanisertib Potently Inhibits Multiple Plasmodium Kinases and Life Cycle Stages.”
Science Translational Medicine, vol. 14, no. 667, Oct. 2022, p. eabo7219,
https://doi.org/10.1126/scitranslmed.abo7219.
Cite
Arendse, Lauren B., et al. “Plasmodium Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities.”
ACS Infectious Diseases, vol. 7, no. 3, Mar. 2021, pp. 518–34,
https://doi.org/10.1021/acsinfecdis.0c00724.
Cite
Vanaerschot, Manu, et al. “Inhibition of Resistance-Refractory P. Falciparum Kinase PKG Delivers Prophylactic, Blood Stage, and Transmission-Blocking Antiplasmodial Activity.”
Cell Chemical Biology, vol. 27, no. 7, July 2020, pp. 806-816.e8,
https://doi.org/10.1016/j.chembiol.2020.04.001.
Cite
Arendse, Lauren B., et al. “Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.”
Pharmacological Reviews, edited by Eric L. Barker, vol. 71, no. 4, Oct. 2019, pp. 539–70,
https://doi.org/10.1124/pr.118.017129.
Cite